CBLL · CeriBell

The thesis

CeriBell's delirium monitor, launched on 2 November 2026, should add headband usage to a core seizure-monitoring business that grew revenue 30% in the third quarter of 2026, so the shares are modestly more likely than not to beat the S&P 500 over three months. The 2027 revenue guidance due with the fourth-quarter report, expected around late February 2027, settles it, because management said that guidance will give "a more granular perspective" on delirium's revenue impact.

Launch timing is no longer the question. Size is. The Centers for Medicare & Medicaid Services (CMS) approved a New Technology Add-on Payment (NTAP) of up to $2,171 per eligible inpatient case, effective 1 October 2026 (CeriBell's NTAP announcement of 3 August 2026). The 3 November 2026 report turned delirium from a pilot into a sold product without attaching a usage figure. Core usage is strong, while operating costs still grow faster than sales.

Bullish and bearish views on CeriBell, Inc.

The bull case on CeriBell, Inc. (CBLL), in brief: launch is commercial. The bear case: expenses still outgrow sales.

Bull case

• Launch is commercial. CeriBell announced the commercial launch of its delirium monitoring solution on 2 November 2026 (company news). It ships as a software upgrade, so existing accounts can adopt it without new hardware.
• Pilot customers used more headbands. CEO Jane Chao cited a "material increase in headband utilization" at pilot sites on the 3 November 2026 call (transcript). The gains lasted at least 120 days at the earliest customers and appeared before the payment began.
• Core business is gaining accounts. Third-quarter revenue was $29.3 million, up 30% from a year earlier, with 747 active accounts after a record 35 net additions (3 November 2026 results). Chao said usage per account grew at a double-digit rate, the highest since the initial public offering.
• Guidance leaves delirium out. Full-year 2026 revenue guidance rose to $115 million–$117 million from $114 million–$117 million on 3 November 2026. It excludes material contributions from delirium, neonate and pediatric products, so any delirium revenue sits outside the range.
• Analyst targets sit above the shares. Canaccord Genuity's target is $33, and BofA Securities raised its target to $31 from $26, both reported on 4 November 2026 after the third-quarter report.

Bear case

• Expenses still outgrow sales. Third-quarter operating expenses were $46.9 million, up 36% from a year earlier, against 30% revenue growth. The second quarter showed the same pattern, at 37% against 33%.
• Losses widened. The third-quarter net loss was $21.4 million, or $0.55 per share, against a $0.51 loss estimate (Benzinga, 3 November 2026). Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) was a $12.1 million loss, compared with a $9.2 million loss a year earlier.
• Margin is guided lower. Gross margin was 90% in the third quarter, after 92% in the second, which included a one-time tariff refund. CFO Scott Blumberg said on 3 November 2026 that CeriBell expects margins "in the high 80% range going forward" on current tariff policy and inventory.
• Delirium carries no new fee. It has no subscription increase and no minimum volume commitment, per the 3 November 2026 call. Revenue depends on hospitals using more headbands, and Chao said it is "a bit too early" to quantify the lift.
• Insiders have been selling. Director Joseph Michael Taylor sold 10,200 shares at $27.22 on 9 November 2026, and Chief Technology Officer Raymond Woo sold 4,887 shares at $26.96 on 2 November 2026 under a Rule 10b5-1 plan (SEC Form 4 filings). CEO Xingjuan Chao sold 20,846 shares at $25.03 on 15 September 2026 under a similar plan.

Price setup

The shares closed at $26.35 on 12 November 2026, down from $27.80 on 11 November 2026. That is 8.8% below the 52-week intraday high of $28.89, set on 3 November 2026, the day of the third-quarter report. The 3-month change is 12.9%, measured from a close of $23.33 on 14 August 2026.

The close sits above the 50-day average of $25.49 and the 200-day average of $21.01. The 52-week closing low was $12.49 on 13 November 2025. The market has already paid for the NTAP approval and the launch: the shares hold most of the post-report gain while the analyst targets of $31 and $33 sit above the last close.

Catalysts ahead

• ~31 December 2026 (est.): Limited market release of the Omni hardware platform, which management said begins in the fourth quarter of 2026. Shows whether the second product due to drive 2027 growth is on schedule alongside the delirium rollout.
• ~25 February 2027 (est.): Fourth-quarter 2026 results and 2027 revenue guidance. Management said 2027 guidance will give more detail on delirium's revenue impact; it is the first scheduled test of the size of the usage lift.

What would change the view

A weekly close below $23.00, which would erase the October advance and show the market rejecting delirium as a revenue driver; 2027 revenue guidance that shows no measurable delirium contribution would also break the case.

The risks this note tracks, each with what would confirm it:

• The delirium usage lift seen at pilot intensive-care sites does not repeat at wider launched accounts, leaving a no-fee upgrade with little added headband revenue. Confirmed by: 2027 guidance with no measurable delirium contribution, or usage per account growth falling below a double-digit rate.
• Operating expenses keep growing faster than revenue. Confirmed by: a further quarterly report repeating the third-quarter 2026 pattern of 36% expense growth against 30% revenue growth.
• Gross margin falls further as the one-time second-quarter 2026 tariff refund fades and tariff policy shifts. Confirmed by: a reported gross margin below the high 80% range management described on 3 November 2026.
• Veterans Affairs accounts dilute average usage because top-down launches start below the average account. Confirmed by: management citing Veterans Affairs mix as a drag on usage per account in the fourth-quarter 2026 report.
• The temporary Medicare add-on payment, limited to no more than three years, ends or is cut before hospitals build delirium into routine use. Confirmed by: a CMS payment-rule change affecting the delirium add-on, or management citing hospital reimbursement hesitancy on an earnings call.

What it trades with

The shares have moved mainly on company events: the NTAP approval on 3 August 2026 and the third-quarter report on 3 November 2026. Medicare inpatient payment policy is the main outside driver, because the delirium add-on payment runs no more than three years for a given indication, per CeriBell's 11 May 2026 Form 10-Q. As a loss-making small-cap device maker with a $21.4 million third-quarter net loss, CeriBell is also exposed to swings in investor appetite for unprofitable medical-technology growth names.